Supernus Pharmaceuticals

Pioneering New Medicines in Neurology and Psychiatry With more than 20 years of experience, we are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) disorders. In 2013 we launched Oxtellar XR® and Trokendi XR®, two novel neurology products for the treatment of epilepsy. We are also developing several product candidates in psychiatry to address unmet medical needs and opportunities in attention-deficit hyperactivity disorder (ADHD) and its coexisting disorders, and depression. We are developing differentiated products by leveraging our proprietary and in-licensed technologies. We use such technologies to discover and develop novel uses for known drug compounds and to enhance their therapeutic benefits. Our focus on known drug compounds with established mechanisms of action reduces the risks, costs, and time typically associated with pharmaceutical product development.
Rockville, US
344 (est)+12%
Supernus Pharmaceuticals was founded in 2005 and is headquartered in Rockville, US

Key People at Supernus Pharmaceuticals

Jack A. Khattar

Jack A. Khattar

President and CEO

Supernus Pharmaceuticals Locations

Rockville, US

Supernus Pharmaceuticals Metrics

Supernus Pharmaceuticals Summary

Market capitalization

$1.16 B

Closing share price

Supernus Pharmaceuticals's current market capitalization is $1.16 B.

Supernus Pharmaceuticals Financials

Supernus Pharmaceuticals's revenue is $144 M in FY, 2015 which is 18.34% increase from the previous period.
FY, 2013FY, 2014FY, 2015


$12 M$122 M$144 M

Gross profit

$10.9 M$116 M$136 M

Operating income

$-61.9 M$24.2 M$17.7 M

Operating expense total

$72.8 M$92.1 M$118 M

Net Income

$-92.3 M$19.9 M$14 M

Operating cash flow

$-7.32 M$3.42 M$-2.24 M

    Supernus Pharmaceuticals Market Value History

    Supernus Pharmaceuticals News

    Supernus Pharmaceuticals Company Life

    You may also be interested in